VEGFA and small cell lung carcinoma: AK112, a bispecific antibody targeting PD-1 and VEGF-A, demonstrated favorable safety and preliminary efficacy in a phase Ib trial evaluating its combination with chemotherapy as first-line treatment for ES-SCLC.